Zealand Pharma A/S

CHI Family conference

Vienna, 22nd September 2019

Klara Owen, MD, PhD.
Medical Director

Forward-looking statements

This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or any other information transmitted or made available to the viewer or recipient hereof, whether communicated in written or oral form.

This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire Zealand securities, in any jurisdiction, or an inducement to enter into investment activity, nor shall there be any sale of Zealand securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This presentation contains forward-looking statements that reflect management's current views with respect to Zealand's product candidates' development, clinical and regulatory timelines and anticipated results, market opportunity, potential financial performance and other statements of future events or conditions. Although Zealand believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors, many of which are beyond Zealand’s control. No reliance should be made on such forward-looking statements.

Zealand does not intend to update the presentation, including the forward-looking statements contained therein, following distribution, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that lead to changes compared to the date when these statements were provided.

Zealand Pharma in brief

Danish Biotech

Founded in Copenhagen (HQ) in 1998, opened U.S. subsidiary 2018

Leading Peptide Platform

A world leading peptide platform, with two medicines on the market

Three Phase 3 Programs

Accelerating several late stage programs to launch new products into major markets in 2 to 4 years

Expanding Capabilities

Transforming into a fully integrated biotech company with U.S. commercial organization

Experienced Team

172 employees of which 83% are in R&D

Dual Nasdaq Listing

Traded in Copenhagen and New York (ZEAL)

ZEALAND PHARMA

Dasiglucagon

- Stable glucagon analog
- Dissolved in water
- Fast onset-of-action
- Suitable for multiple indication

Diabetes care



HypoPal® rescue pen for severe hypoglycemia
Phase 3 trials finalized, positive results

Automated diabetes care with a dual hormone bionic pancreas
Phase 3 ready

CHI, rare disease

Continuous infusion for prevention and treatment of low blood glucose in congenital hyperinsulinism (CHI)
Phase 3 initiated

ZEALAND PHARMA

Dasiglucagon as long-term treatment for newborns, infants and children with congenital hyperinsulinism

- Providing a non-surgical treatment option
- Liquid formulation, stable at room and body temperature
- Two Phase 3 trial initiated
- EU and U.S. orphan drug designation granted

For information on ongoing clinical trials

- Visit EU clinical trials register and search for ‘dasiglucagon’, or ‘Zealand Pharma’

  https://www.clinicaltrialsregister.eu/ctr-search/search

- Or US clinicaltrials.gov

  https://clinicaltrials.gov/

- Talk to your care team
  - Participating centers in Germany: Düsseldorf, Magdeburg
  - In UK: London, Manchester, Liverpool, Glasgow
  - Israel: Jerusalem

ZEALAND PHARMA

Treatment for children with CHI during both diagnostic and treatment periods

Before full diagnosis

Glucose level stabilization
Limiting hypoglycemia

After full diagnosis

Limiting or avoiding hypoglycemia

Dasiglucagon infusion for short-term glycemic stabilization

- Short term therapy difficult-to-manage persistent hypoglycemia
- Replacement of diazoxide or glucagon i.v. infusion[1]
- Opportunity for earlier discharge home

Dasiglucagon infusion for long-term treatment

- Long-term stabilization of glucose levels, avoidance of severe lows in of diffuse CHI patients
- Elimination or reduction of other drug treatments[2]
- Reduced need for pancreatectomy

[1] Up to 72% of patients are diazoxide non-responsive, Arya VB, et al. PLoS One. 2014;9(5):e98054, N=417;
[2] E.g. diazoxide, somatostatin analogs, nutritional support and central venous catheter.

ZEALAND PHARMA

Dasiglucagon hopes to address unmet medical need

‘Prevention and treatment of hypoglycemia in children with CHI, 7 days of age and older’

Trial ZP4207-17109
in up to 32 older children
with difficult-to-manage CHI

Age 3 months to 12 years
Primary endpoint:
- Reduction in weekly hypoglycemic events

10 children included

Trial ZP4207-17103
in up to 12 younger children
with newly-diagnosed persistent hypoglycemia

Age 7 days to 1 year
Primary endpoint:
- Reduction in intravenous glucose infusion

Initiation late 2019

Trial ZP4207-17106
Long term extension
All children benefiting from dasiglucagon in previous trials

Long-term safety and efficacy of dasiglucagon for treatment CHI.

3 children included

ZEALAND PHARMA